• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scilex Holding Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    3/20/25 4:29:17 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCLX alert in real time by email
    8-K
    0001820190false00018201902025-03-192025-03-190001820190sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf1150PerShareMember2025-03-192025-03-190001820190sclx:CommonStockParValue00001PerShare2Member2025-03-192025-03-19

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _______________________

    FORM 8-K
    _______________________

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): March 19, 2025

    _______________________

    SCILEX HOLDING COMPANY
    (Exact name of registrant as specified in its charter)

    _______________________

    Delaware
    (State or other jurisdiction
    of incorporation)

    001-39852
    (Commission
    File Number)

    92-1062542
    (IRS Employer
    Identification No.)

     

    960 San Antonio Road, Palo Alto, California, 94303
    (Address of principal executive offices, including zip code)

    (650) 516-4310

    Registrant’s telephone number, including area code

    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    _______________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

    (Title of each class)

    (Trading Symbol)

    (Name of exchange on which registered)

    Common Stock, par value $0.0001 per share

    SCLX

    The Nasdaq Stock Market LLC

    Warrants to purchase one share of common stock, each at an exercise price of $11.50

    SCLXW

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     


     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On March 19, 2025, Scilex Holding Company (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, a total of (i) 29,057,097 shares of the Company’s Series A preferred stock, $00001 par value per share (the “Series A Preferred Stock”), or 100% of the 29,057,097 shares of Series A Preferred Stock, issued and outstanding, and (ii) 169,406,091 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), or approximately 70% of the 243,312,885 shares of Common Stock, issued and outstanding as of the close of business on February 24, 2025, the record date for the Special Meeting, were represented virtually or by proxy.

     

    The holders of Series A Preferred Stock were entitled to vote, together with the holders of Common Stock and not separately as a class, on an as converted to Common Stock basis for an aggregate of 32,596,097 votes as a result of the adjustments to the deemed conversion price of such preferred stock in accordance with the Certificate of Designations of Series A Preferred Stock, filed with the Delaware Secretary of State on November 10, 2022.

     

    At the Special Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on February 27, 2025.

     

    Set forth below is a brief description of each proposal voted upon at the Special Meeting and the voting results with respect to each proposal.

     

    Proposal No. 1: To approve any amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock, within a range of 1-for-14 to 1-for-50 (or any number in between), without reducing the authorized number of shares of the Common Stock, and the filing of a final amendment with the ratio within such range to be determined in the sole discretion of the Board of Directors of the Company at any time on or before March 19, 2026, without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split Proposal”).

     

    Votes For

    Votes Against

    Abstentions

    151,124,713

    49,235,399

    1,642,350

     

    Proposal No. 2: To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal.

     

    Votes For

    Votes Against

    Abstentions

    151,840,294

    47,342,114

    2,820,054

     

    An adjournment of the Special Meeting was not necessary because there were sufficient votes in favor of the Reverse Stock Split Proposal.

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    104

    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     

    2

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    SCILEX HOLDING COMPANY

     

     

     

     

    By:

    /s/ Jaisim Shah

     

    Name:

    Jaisim Shah

    Date: March 20, 2025

    Title:

    Chief Executive Officer and President

     

    3

     


    Get the next $SCLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCLX

    DatePrice TargetRatingAnalyst
    1/27/2025$22.00Buy
    D. Boral Capital
    10/16/2024$14.00Buy
    Alliance Global Partners
    6/13/2024$13.00Buy
    Rodman & Renshaw
    10/16/2023$4.00Buy
    B. Riley Securities
    10/13/2023$4.00Buy
    B. Riley Securities
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scilex Holding Co exercised 263,914,094 in-the-money shares at a strike of $0.00 and sold $871,161 worth of shares (422,299 units at $2.06), increasing direct ownership by 16,358% to 265,102,560 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    11/28/25 9:44:09 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Scilex Holding Co claimed ownership of 1,610,765 shares (SEC Form 3)

    3 - Scilex Holding Co (0001820190) (Reporting)

    11/28/25 9:41:56 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Wu Yue Alexander

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/9/25 8:47:29 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    SEC Filings

    View All

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    12/12/25 4:45:27 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    12/12/25 4:43:37 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Scilex Holding Company

    424B3 - Scilex Holding Co (0001820190) (Filer)

    12/12/25 4:40:14 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $SCLX
    Leadership Updates

    Live Leadership Updates

    View All

    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    12/18/24 7:04:41 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/31/24 12:44:57 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/29/24 6:59:31 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    D. Boral Capital initiated coverage on Scilex Holding with a new price target

    D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

    1/27/25 8:08:33 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on Scilex Holding with a new price target

    Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

    10/16/24 8:01:57 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

    Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

    6/13/24 7:16:15 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

    7/23/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

    PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

    3/4/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Inc. (NASDAQ: DVLT) Announces a Distribution Date of Dec. 24, 2025, for the Dream Bowl Meme Coin Tokens to All Eligible Record Equity Holders of Datavault AI and Holders of Common Stock of Scilex Holding Company

    PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

    12/11/25 4:05:00 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

    Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (NASDAQ:DVLT, "Datavault AI")) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment).The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI's November 24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant.Scilex has exercised the warrant in full and the shares of Datavault AI common stock issued upon such exercise have an approximate value of $583.3 million based on the closing price of $2.21 per share of D

    11/26/25 6:00:00 AM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Announces Closing of the Second Tranche of Scilex Holding Company's Previously Announced Equity Financing

    Second tranche closing of approximately 1,237.6 Bitcoin follows approval by Datavault AI's stockholders at annual meeting.Scilex Holding Company purchased a pre-funded warrant exercisable for approximately 263.91 million shares of Datavault AI common stock in connection with the closing of this second tranche.Both companies ramping up collaboration to deliver growth in 2026. PHILADELPHIA, Nov. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault® AI (NASDAQ:DVLT, "Datavault" or the "Company")), a provider of data monetization, credentialing, and real-world asset tokenization technologies, today announces that it has closed the second tranche of its previously announced equity financing wi

    11/26/25 6:00:00 AM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Financials

    Live finance-specific insights

    View All

    Datavault AI Inc. (NASDAQ: DVLT) Announces a Distribution Date of Dec. 24, 2025, for the Dream Bowl Meme Coin Tokens to All Eligible Record Equity Holders of Datavault AI and Holders of Common Stock of Scilex Holding Company

    PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

    12/11/25 4:05:00 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

    PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault A

    11/21/25 3:59:33 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin

    PHILADELPHIA, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, announced today that, in connection with its previously announced distribution of Dream Bowl 2026 Meme Coins to eligible record equity holders of Datavault AI, Nasdaq has informed the Company that it is not expecting to quote an ex-dividend date for such distribution and therefore eligible record equity holders of Datavault AI must be holders as of the record date of November 25, 2025 in order to receive the distribution.  With respect to Datavault AI's volunta

    11/21/25 3:56:48 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    4/25/24 5:25:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    3/5/24 4:22:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care